Astellas Pharma Inc. (ALPMF)
USD 10.12
(0.0%)
USD 10.12
(0.0%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 1212.36 Billion JPY | 6.58% |
| 2023 | 1230.26 Billion JPY | 17.94% |
| 2022 | 1043.15 Billion JPY | 3.96% |
| 2021 | 1003.46 Billion JPY | -2.02% |
| 2020 | 1024.1 Billion JPY | 0.97% |
| 2019 | 1014.29 Billion JPY | 0.82% |
| 2018 | 1006.06 Billion JPY | 1.5% |
| 2017 | 991.16 Billion JPY | -4.43% |
| 2016 | 1037.11 Billion JPY | 13.46% |
| 2015 | 914.06 Billion JPY | 12.95% |
| 2014 | 809.28 Billion JPY | 18.75% |
| 2013 | 681.48 Billion JPY | 4.72% |
| 2012 | 650.75 Billion JPY | -1.1% |
| 2011 | 657.97 Billion JPY | -4.03% |
| 2010 | 685.63 Billion JPY | -2.23% |
| 2009 | 701.26 Billion JPY | 1.16% |
| 2008 | 693.24 Billion JPY | 8.9% |
| 2007 | 636.56 Billion JPY | 4.98% |
| 2006 | 606.36 Billion JPY | 98.24% |
| 2005 | 305.88 Billion JPY | -9.35% |
| 2004 | 337.41 Billion JPY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 317.73 Billion JPY | 3.82% |
| 2024 Q3 | 346.03 Billion JPY | 8.91% |
| 2024 Q4 | 308.72 Billion JPY | -10.78% |
| 2024 Q1 | 306.04 Billion JPY | 4.82% |
| 2024 FY | 1212.36 Billion JPY | -1.45% |
| 2023 Q2 | 317.61 Billion JPY | 8.43% |
| 2023 Q3 | 327.75 Billion JPY | 3.19% |
| 2023 Q4 | 291.97 Billion JPY | -10.92% |
| 2023 FY | 1230.26 Billion JPY | 17.94% |
| 2023 Q1 | 292.92 Billion JPY | 19.58% |
| 2022 Q4 | 244.95 Billion JPY | -9.7% |
| 2022 FY | 1043.15 Billion JPY | 3.96% |
| 2022 Q1 | 263.91 Billion JPY | 5.44% |
| 2022 Q2 | 263.01 Billion JPY | -0.34% |
| 2022 Q3 | 271.26 Billion JPY | 3.14% |
| 2021 Q3 | 257.24 Billion JPY | 3.47% |
| 2021 Q4 | 250.29 Billion JPY | -2.7% |
| 2021 FY | 1003.46 Billion JPY | -2.02% |
| 2021 Q1 | 247.31 Billion JPY | -3.85% |
| 2021 Q2 | 248.61 Billion JPY | 0.53% |
| 2020 Q4 | 257.21 Billion JPY | 0.75% |
| 2020 FY | 1024.1 Billion JPY | 0.97% |
| 2020 Q2 | 247.97 Billion JPY | -5.94% |
| 2020 Q3 | 255.29 Billion JPY | 2.95% |
| 2020 Q1 | 263.62 Billion JPY | 11.24% |
| 2019 Q1 | 258.34 Billion JPY | 5.21% |
| 2019 FY | 1014.29 Billion JPY | 0.82% |
| 2019 Q2 | 245.2 Billion JPY | -5.09% |
| 2019 Q3 | 273.76 Billion JPY | 11.64% |
| 2019 Q4 | 236.98 Billion JPY | -13.44% |
| 2018 Q3 | 269.58 Billion JPY | 8.86% |
| 2018 FY | 1006.06 Billion JPY | 1.5% |
| 2018 Q1 | 243.29 Billion JPY | 2.95% |
| 2018 Q2 | 247.63 Billion JPY | 1.78% |
| 2018 Q4 | 245.54 Billion JPY | -8.91% |
| 2017 Q4 | 236.33 Billion JPY | -5.22% |
| 2017 Q3 | 249.35 Billion JPY | 4.26% |
| 2017 FY | 991.16 Billion JPY | -4.43% |
| 2017 Q2 | 239.18 Billion JPY | -10.18% |
| 2017 Q1 | 266.28 Billion JPY | 10.07% |
| 2016 FY | 1037.11 Billion JPY | 13.46% |
| 2016 Q1 | 253.58 Billion JPY | 14.86% |
| 2016 Q4 | 241.93 Billion JPY | -12.36% |
| 2016 Q3 | 276.06 Billion JPY | 3.97% |
| 2016 Q2 | 265.52 Billion JPY | 4.71% |
| 2015 Q1 | 219.17 Billion JPY | 12.55% |
| 2015 Q2 | 216.18 Billion JPY | -1.36% |
| 2015 Q3 | 257.93 Billion JPY | 19.31% |
| 2015 FY | 914.06 Billion JPY | 12.95% |
| 2015 Q4 | 220.76 Billion JPY | -14.41% |
| 2014 Q1 | 189.22 Billion JPY | 10.04% |
| 2014 Q3 | 227.26 Billion JPY | 14.75% |
| 2014 Q2 | 198.04 Billion JPY | 4.66% |
| 2014 FY | 809.28 Billion JPY | 18.75% |
| 2014 Q4 | 194.74 Billion JPY | -14.31% |
| 2013 Q2 | 156.79 Billion JPY | -7.66% |
| 2013 Q3 | 182.93 Billion JPY | 16.67% |
| 2013 Q4 | 171.95 Billion JPY | -6.0% |
| 2013 FY | 681.48 Billion JPY | 4.72% |
| 2013 Q1 | 169.79 Billion JPY | 32.19% |
| 2012 FY | 650.75 Billion JPY | -1.1% |
| 2012 Q1 | 174.13 Billion JPY | 16.73% |
| 2012 Q2 | 161.56 Billion JPY | -7.22% |
| 2012 Q4 | 128.45 Billion JPY | -31.16% |
| 2012 Q3 | 186.6 Billion JPY | 15.5% |
| 2011 Q3 | 185.65 Billion JPY | 20.2% |
| 2011 Q2 | 154.45 Billion JPY | -8.44% |
| 2011 Q1 | 168.68 Billion JPY | 14.79% |
| 2011 FY | 657.97 Billion JPY | -4.03% |
| 2011 Q4 | 149.17 Billion JPY | -19.65% |
| 2010 Q3 | 187.78 Billion JPY | 7.69% |
| 2010 FY | 685.63 Billion JPY | -2.23% |
| 2010 Q4 | 146.95 Billion JPY | -21.74% |
| 2010 Q1 | 176.53 Billion JPY | 17.7% |
| 2010 Q2 | 174.36 Billion JPY | -1.23% |
| 2009 FY | 701.26 Billion JPY | 1.16% |
| 2009 Q2 | 176.42 Billion JPY | 0.0% |
| 2009 Q3 | 194.67 Billion JPY | 10.34% |
| 2009 Q4 | 149.99 Billion JPY | -22.95% |
| 2008 FY | 693.24 Billion JPY | 8.9% |
| 2007 FY | 636.56 Billion JPY | 4.98% |
| 2006 FY | 606.36 Billion JPY | 98.24% |
| 2005 FY | 305.88 Billion JPY | -9.35% |
| 2004 FY | 337.41 Billion JPY | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AstraZeneca PLC | 34.69 Billion USD | -3394.54% |
| Bristol-Myers Squibb Company PFD CONV 2 | 34.31 Billion USD | -3433.259% |
| CSPC Pharmaceutical Group Limited | 30.13 Billion USD | -3922.696% |
| Clarus Therapeutics Holdings, Inc. | 11.23 Million USD | -10788962.917% |
| Novartis AG | 34.18 Billion USD | -3446.177% |
| PT Kalbe Farma Tbk. | 743.47 Million USD | -162968.028% |